VTRS: second_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/cc054f31-02d3-4941-b574-2955abb00d0c/","filing_uuid":"cc054f31-02d3-4941-b574-2955abb00d0c","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/cc054f31-02d3-4941-b574-2955abb00d0c/print/","filing_document_content_type":"text/html","income":null,"expenses":"360000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Peter Wallace","dt_posted":"2026-07-20T20:26:57-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1000 Mylan Boulevard","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Canonsburg","registrant_state":"PA","registrant_zip":"15317","registrant":{"id":26353,"url":"https://lda.gov/api/v1/registrants/26353/","house_registrant_id":33792,"name":"VIATRIS INC.","description":null,"address_1":"1000 Mylan Boulevard","address_2":null,"address_3":null,"address_4":null,"city":"Canonsburg","state":"PA","state_display":"Pennsylvania","zip":"15317","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PETER WALLACE","contact_telephone":"+1 202-507-5356","dt_updated":"2026-07-30T15:07:39.090404-04:00"},"client":{"id":134178,"url":"https://lda.gov/api/v1/clients/134178/","client_id":12,"name":"VIATRIS INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"PA","state_display":"Pennsylvania","country":"US","country_display":"United States of America","ppb_state":"PA","ppb_state_display":"Pennsylvania","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-14"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66369,"prefix":null,"prefix_display":null,"first_name":"KATHARINE","nickname":null,"middle_name":null,"last_name":"HAYES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69928,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"WALLACE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"IP Issues related to generic medicines Patent Settlements","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69928,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"WALLACE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66369,"prefix":null,"prefix_display":null,"first_name":"KATHARINE","nickname":null,"middle_name":null,"last_name":"HAYES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":72530,"prefix":null,"prefix_display":null,"first_name":"ANNE","nickname":null,"middle_name":null,"last_name":"WILSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Trade issues related to generic medicines Pharmaceutical supply chain S.3778: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act S.3841: Last Sale Valuation Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69928,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"WALLACE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66369,"prefix":null,"prefix_display":null,"first_name":"KATHARINE","nickname":null,"middle_name":null,"last_name":"HAYES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FIN","general_issue_code_display":"Financial Institutions/Investments/Securities","description":"Policy related to corporate governance","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":72530,"prefix":null,"prefix_display":null,"first_name":"ANNE","nickname":null,"middle_name":null,"last_name":"WILSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"S.2296 National Defense Authorization Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69928,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"WALLACE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}